Here's what investors still don't know after Cronos Group reported its Q4 results.
Recreational marijuana sales and increased cannabis oil sales fueled revenue growth, but the company's costs are going up.
Which of these struggling gene-editing biotechs is most likely to win over the long run?
It's a no-go for recreational marijuana in the Garden State for now. And several marijuana stocks are feeling the sting of the state's delay.
A new report reveals why marijuana investors really need to be paying attention to what's going on in Europe.
Can these big high-flying stocks keep the momentum going?
What do a beaten-down biotech, a giant pharmacy chain, and a robotic surgical systems maker have in common? They could all be great stocks to buy.
These stocks are dirt cheap. But perhaps not for too much longer.
These top marijuana stocks look really expensive. But can these looks be deceiving?
Hint: In pretty good shape.
There's plenty to like about this hot Canadian marijuana stock. But some reason for caution, too.
This limited partnership checks off all the boxes.
You might be surprised why RBC Capital Markets is so bullish about the big biotech stock.
Which stock wins in a matchup between a top Canadian marijuana producer and a leading beer maker with a big stake in cannabis?
Which stock wins in a battle between these two successful biotechs?
Thinking outside the box could pay off.
If you're looking for a reason to buy Tilray, this is it.
CVS Health Starts Selling CBD Products: Could This Under-the-Radar Marijuana Stock Be the Big Winner?
It's too early to know if CBD products will fly off the shelves. But this U.S. marijuana stock is flying high after announcing its deal with the pharmacy chain.
The biotech throws in the towel on a drug that some thought could be a game changer in treating Alzheimer's disease. And it's left with a challenging future.
Investors' optimism about the prospects for the biotech's experimental vaccines appears to be increasing.